Your browser version is outdated. We recommend that you update your browser to the latest version.

Development 

We have Worldwide exclusive rights to a novel TLR7 agonist that is a potent stimulator of the innate immune system. The TLR7 agonist has been GMP produced and shown good scale-up and stability properties.

 

Clinical development

We are planning to initiate a phase I study in 2020.